Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-94

Hi Chips,

Ok, so you believe that Admedus and Prof. Frazer have no plans to commence a HSV2 clinical Phase II study and that its HPV vaccine achieving 100% survival rates with 87.5% of study subjects having no detectable tumours after 50 days was just a load of hogwash because as far as you're concerned none of these vaccines even exist...? One only needs to look at the current share price of AHZ to acknowledge what an uniformed market thinks, but as you disclose yourself as a holder, surely you must read some announcements?

PYC is only a drug discovery company so if you are referring to the delivery of peptides via intracellular means this refers to drug delivery inside the cell as opposed to extracellular delivery which refers to delivery outside the cell.

When we refer to the route of administration in pharmacology or toxicology this is the path by which a drug is actually delivered into the body otherwise referred to as pharmacokinetics which relates to the process of uptake, distribution, and elimination of each drug from the body.

Assuming that you're willing to do backflips and acknowledge that the HSV-2 and HPV vaccines developed by Prof Frazer which have already been investigated in independent clinical studies may actually exist, are you still determined to dispute Prof Frazer's opinion that vaccines delivered via the intra-dermal route of administration are going to solve many of the existing problems related to vaccines today?

Prof Frazer's vision of the future is for vaccines that will be administered via the intra-dermal route of delivery with technologies such as the Nanopatch.

If you still don't believe that even the new HSV-2 vaccine developed by Prof. Frazer hasn't been investigated in clinical studies with the use of intra-dermal delivery technologies such as the Nanopatch, just say the word, and I'll be happy to substantiate